Practice 5 structured short- and long-answer medical questions on Weekly Year 2: Microbiology Exam - July 10, 2026 (Sections B & C). Review model answers for...
Answer: 1. Enzymatic inactivation of the antibiotic (e.g., beta-lactamases hydrolyzing penicillins). 2. Alteration of the antibiotic's target site (e.g., mutations in ribosomal RNA genes conferring resistance to macrolides). 3. Reduced drug accumulation (e.g., efflux pumps actively transporting antibiotics out of the cell or decreased permeability of the cell membrane).
Answer: Gram-positive bacteria have a thick peptidoglycan layer external to the cytoplasmic membrane, with teichoic acids embedded. Gram-negative bacteria have a thin peptidoglycan layer located in the periplasmic space, enclosed by an outer membrane containing lipopolysaccharides (LPS). This outer membrane of Gram-negative bacteria acts as a barrier, hindering the entry of large or hydrophobic antibiotics like vancomycin, which target the peptidoglycan synthesis primarily in Gram-positive bacteria. Conversely, antibiotics like penicillin, which inhibit peptidoglycan synthesis, are generally effective against both, though the outer membrane of Gram-negatives can reduce their efficacy.
Answer: The capsule is a polysaccharide or polypeptide layer external to the cell wall. Its significance in pathogenesis includes: 1. antiphagocytic activity, preventing engulfment by host immune cells. 2. adherence to host tissues. 3. preventing desiccation. Examples: - *Streptococcus pneumoniae* (pneumococcal pneumonia, meningitis). - *Haemophilus influenzae* type b (meningitis, epiglottitis).
Answer: A biofilm is a structured community of microorganisms encased within a self-produced extracellular polymeric substance (EPS) matrix, adhering to a surface. Mechanisms contributing to persistent infections: 1. **Increased resistance to antibiotics:** The EPS matrix acts as a physical barrier, slowing antibiotic penetration, and altered metabolic states of bacteria within the biofilm can reduce susceptibility. 2. **Immune evasion:** The biofilm matrix can shield bacteria from host immune cells and complement-mediated killing.
Answer: a) **Likely Pathogen:** The Gram stain showing Gram-positive cocci in pairs and short chains is highly suggestive of *Streptococcus pneumoniae* (pneumococcus). **Pathogenicity:** *S. pneumoniae* is a major cause of community-acquired pneumonia, otitis media, sinusitis, and meningitis. Its virulence factors include: * **Polysaccharide capsule:** Crucial for antiphagocytic activity and adherence. Different serotypes exist, and the capsule is the target of many conjugate vaccines. * **Pneumolysin:** A pore-forming toxin that damages respiratory epithelium, leading to inflammation and tissue damage. * **Autolysins:** Enzymes involved in cell wall degradation, which release cell wall components (like peptidoglycan and teichoic acid) that trigger inflammatory responses. * **Hyaluronidase:** An enzyme that breaks down hyaluronic acid in the extracellular matrix, facilitating bacterial spread. **Potential Complications:** Pneumonia can lead to complications such as empyema (pus in the pleural space), lung abscess, bacteremia (sepsis), and meningitis if the infection spreads to the central nervous system. b) **Laboratory Diagnostic Methods:** * **Sputum Gram Stain and Culture:** Essential for initial presumptive diagnosis and definitive identification. Sputum should be processed for Gram stain and then inoculated onto appropriate culture media (e.g., blood agar, chocolate agar). *S. pneumoniae* is typically a facultative anaerobe and is often seen as alpha-hemolytic on blood agar. * **Optochin Susceptibility Test:** *S. pneumoniae* is characteristically susceptible to optochin, differentiating it from other viridans streptococci which are typically resistant. * **Bile Solubility Test:** *S. pneumoniae* colonies are soluble in bile salts, whereas most other alpha-hemolytic streptococci are not. This is another key identification test. * **Blood Cultures:** Crucial for detecting bacteremia, which can occur in severe pneumonia and is associated with higher mortality. * **Urinary Antigen Detection:** Rapid tests are available for detecting *S. pneumoniae* C-polysaccharide antigen in urine, which can aid in early diagnosis, especially in hospitalized patients. * **Serological Tests:** While not routinely used for initial diagnosis, serological tests for antibodies against specific pneumococcal serotypes can be useful for epidemiological studies or retrospectively confirming infection, particularly for vaccine effectiveness studies. c) **Antimicrobial Therapy:** **Principles:** Treatment aims to eradicate the pathogen and resolve the infection. The choice of antibiotic depends on the likely pathogen, local resistance patterns, patient factors, and severity of illness. **Factors Influencing Drug Choice:** * **Suspected pathogen:** Gram stain results and local epidemiology guide empirical therapy. * **Severity of illness:** Outpatient vs. inpatient (non-ICU vs. ICU) management dictates drug choices and routes of administration. * **Local resistance patterns:** Knowledge of local prevalence of penicillin-resistant *S. pneumoniae* (PRSP) and macrolide-resistant *S. pneumoniae* (MRSP) is critical. * **Patient comorbidities:** Underlying conditions like COPD, diabetes, or immunosuppression may necessitate broader-spectrum antibiotics or longer treatment durations. * **Allergies:** Penicillin allergies require alternative drug classes. **Recommended Regimens (General Principles):** * **Outpatients with no comorbidities:** Amoxicillin or a macrolide (e.g., azithromycin) if local resistance is low. Combination therapy with amoxicillin and a macrolide, or amoxicillin/clavulanate, is also an option. * **Outpatients with comorbidities:** A respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin) or a beta-lactam (e.g., amoxicillin/clavulanate, cefpodoxime, cefuroxime) plus a macrolide. * **Inpatients (non-ICU):** Respiratory fluoroquinolone or a beta-lactam (e.g., ceftriaxone, cefotaxime) plus a macrolide. * **Inpatients (ICU):** Beta-lactam (e.g., ceftriaxone, cefotaxime) plus either azithromycin or a respiratory fluoroquinolone. For patients with risk factors for *Pseudomonas* infection, piperacillin/tazobactam or cefepime plus ciprofloxacin or levofloxacin, with or without azithromycin, may be indicated. **Potential Challenges:** * **Antibiotic Resistance:** Increasingly, *S. pneumoniae* exhibits resistance to penicillin (especially high-level resistance) and macrolides. This necessitates the use of higher doses of beta-lactams or alternative drug classes like fluoroquinolones for resistant strains. * **Treatment Failure:** Can occur due to inadequate antibiotic choice, drug resistance, poor patient adherence, or complications like empyema. * **Adverse Drug Reactions:** Patients may experience side effects from antibiotics, necessitating a change in therapy.